Aspire-Lakewood Holdings, Inc. ASBP
Biotechnology: Pharmaceutical Preparations · IPO 2022 · data as of November 13, 2026
Aspire-Lakewood Holdings, Inc. (ASBP) is a healthcare company listed in the US with a market value of about $12M. In the twelve months to June 30, 2026 it had revenue of $97659 and net income of -$11M, a net margin of -11314.1%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
About Aspire-Lakewood
Aspire-Lakewood is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2022. It was profitable in 2 of the last 4 years in our data. It spends 14897% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 4 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $97659 | $6202 | — | — | — |
| Net income | -$11M | -$24M | -$1M | $4M | $3M |
| Free cash flow | -$7M | -$5M | -$265186 | — | — |
| EPS (diluted) | $-7.39 | $-16.38 | $-1.90 | — | — |
| Net margin | -11314.1% | -394700.0% | — | — | — |
| ROIC | — | — | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Aspire-Lakewood pay a dividend?
Not currently.
Is Aspire-Lakewood a good stock to buy?
We do not give buy or sell advice. Aspire-Lakewood scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.